Since the discovery of stem cells and multipotency characteristics of mesenchymal stem cells (MSCs), there has been tremendous development in regenerative medicine. MSCs derived from bone marrow have been widely used in various research applications, yet there are limitations such as invasiveness of obtaining samples, low yield and proliferation rate, and questions regarding their practicality in clinical applications. Some have suggested that MSCs from other sources, specifically those derived from palatine tonsil tissues, that is, tonsil-derived MSCs (TMSCs), could be considered as a new potential therapeutic tool in regenerative medicine due to their superior proliferation rate and differentiation capabilities with low immunogenicity and ease of obtaining. Several studies have determined that TMSCs have differentiation potential not only into the mesodermal lineage but also into the endodermal as well as ectodermal lineages, expanding their potential usage and placing them as an appealing option to consider for future studies in regenerative medicine. In this review, the differentiation capacities of TMSCs and their therapeutic competencies from past studies are addressed. STEM CELLS 2019;37:1252-1260
SIGNIFICANCE STATEMENTMesenchymal stem cells (MSCs) are considered as a great candidate for tissue engineering in regenerative medicine. Tonsil-derived MSCs (TMSCs) could be an attractive option for clinical applications because of their noninvasiveness of tissue collection, relatively high proliferation rate, and low allogenicity. This review addresses potential differentiation capabilities of TMSCs into mesodermal, endodermal, and ectodermal lineages reported from previous in vitro and in vivo studies as well as their potential applications for treating various human diseases.